Shares of Assembly Biosciences, Inc. (NASDAQ: ASMB) have garnered a consensus recommendation of “Moderate Buy” from analysts, according to MarketBeat. The seven ratings firms monitoring the stock have issued varied assessments, with one analyst recommending a sell, one a hold, and five advocating for a buy. The average target price over the next twelve months is set at $41.75.
Analysts have recently provided insights on ASMB shares. HC Wainwright reaffirmed a “buy” rating and established a price target of $50.00 in a report released on December 22, 2023. Mizuho set a target of $40.00 and classified the stock as “outperform” in a report dated November 20, 2023. In contrast, Weiss Ratings maintained a “sell (D-)” rating in their assessment on January 21, 2024.
Institutional Investment Trends
Several hedge funds and institutional investors have recently made adjustments to their holdings in Assembly Biosciences. Informed Momentum Co LLC increased its stake by 1.6% in the fourth quarter, now owning 29,523 shares valued at approximately $1,004,000, after acquiring an additional 451 shares. Similarly, ADAR1 Capital Management LLC boosted its position by 4.2%, bringing its total to 19,747 shares valued at $672,000 after purchasing an additional 800 shares.
In addition, Geode Capital Management LLC increased its holdings by 0.9%, now owning 131,307 shares worth around $4,468,000 after acquiring 1,212 shares. Palumbo Wealth Management LLC raised its stake by 7.2%, owning 37,305 shares valued at approximately $1,269,000 after acquiring 2,507 shares. Notably, Bank of America Corp DE significantly expanded its position by 6,382.7% during the third quarter, now holding 3,371 shares valued at $86,000 following an acquisition of 3,319 shares.
Currently, institutional investors hold approximately 19.92% of Assembly Biosciences’ stock.
Company Overview
Assembly Biosciences, Inc. is a clinical-stage biotechnology firm focused on developing novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company specializes in small-molecule modulation of viral proteins and host-targeted pathways, aiming for sustained viral suppression and potential functional cures.
The company’s research integrates medicinal chemistry, structural biology, and translational virology to advance its product pipeline from initial discovery to clinical development. Assembly’s lead programs include core protein allosteric modulators (CpAMs), which aim to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication. Additionally, the company is developing prenylation inhibitors targeting the HDV lifecycle.
Investors and analysts alike are closely watching Assembly Biosciences as it navigates its clinical developments and market presence in the biopharmaceutical sector.
